MétaCan
Menu
Back to cohort

Survival following locoregional recurrence in breast cancer by clinical subtype.

2021· article· en· W3172851126 on OpenAlexaff
Kirsten Allen, Caroline Lohrisch, Dan Le, Rekha M. Diocee, Caroline Speers, Alan Nichol, Sara Taylor

Bibliographic record

VenueJournal of Clinical Oncology · 2021
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsSpinal Cord Injury BCKelowna General Hospital
Fundersnot available
KeywordsMedicineBreast cancerInternal medicineCohortOncologyCancerMastectomyEstrogen receptorRadiation therapyTriple-negative breast cancerStage (stratigraphy)Metastasis

Abstract

fetched live from OpenAlex

543 Background: We sought to explore the impact of locoregional recurrence (LRR) on survival in breast cancer (BC) patients in British Columbia treated in the modern era. Methods: A retrospective cohort study design identified patients diagnosed with stage I-III BC from 04/2005-12/2013 treated with surgery and who had a subsequent LRR. Exclusions were death or distant metastasis within 120 days of LRR, bilateral previous/synchronous BC, and other invasive cancers. After LRR, overall survival (OS) and factors associated with OS, including clinical subtype and adjuvant therapy (AdTx), were examined. We defined clinical subtypes as: Luminal (Lum) A-estrogen receptor (ER) and progesterone receptor (PR) positive, HER2 negative, and grade 1 or 2; Lum B-as Lum A but grade 3, or as Lum A but only one of ER or PR positive; triple negative (TNBC)-ER and PR and HER2 negative; and HER2 positive (with any ER, PR). In the absence of earlier LRR, we defined adequate AdTx as: (a) TNBC: >=50% of planned chemotherapy (Chx), (b) HER2 positive: >=50% of planned Chx and >=8 cycles of anti-HER2 therapy, (c) Lum A, B: >=4 years of endocrine therapy and (d) after partial mastectomy or positive final margins: >=50% of radiation therapy dosage. Results: The final cohort had 492 patients with a median follow-up of 7.2 years from LRR and 11.8 years from diagnosis. LRR was local in 69.3% (n=341) and regional +/- local in 30.7% (n=151). Compared with local only, regional recurrences were associated with higher T and N stage, grade, and Lum status (p<=0.01). Biomarkers were re-evaluated at LRR in 82% and changed from initial diagnosis in 32% of those tested: ER expression 3.8% gain, 6.1% loss; PR expression 9.1% gain, 15.1% loss; HER2 overexpression 3.7% gain and 4.8% loss. Over half of patients (n=255, 52%) did not receive adequate AdTx, either by choice or recommendation. A similar proportion with local vs. regional recurrence had inadequate AdTx. Time to death from 1st LRR did not vary significantly between local vs. regional recurrences (median 2.7 years). OS after LRR was lowest in TNBC (median 3.1 years, 24.2% 10-year OS) and longest in Lum A (median not reached, 64.7% 10-year OS) (Table). Conclusions: Our data provide rates of OS after LRR in the era of modern adjuvant therapy. OS after LRR varied by clinical subtype, with TNBC faring the worst, and Lum A the best. Over half had not received adequate AdTx. Despite similar treatment options, OS after LRR was significantly longer for Lum A than B subtypes, underscoring the need for therapy tailored to biology. OS was low in all other subtypes, emphasizing the importance of avoiding LRR.[Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.061
Threshold uncertainty score0.120

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.093
GPT teacher head0.468
Teacher spread0.375 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicBreast Cancer Treatment StudiesFrench-language works237,207